News | November 07, 2025
Pfizer reports Q3 vaccine sales decline amid challenging US market conditions
Comirnaty, Pfizer’s COVID-19 prevention vaccine, reported global sales of $1.15 billion
Comirnaty, Pfizer’s COVID-19 prevention vaccine, reported global sales of $1.15 billion
Capvaxive has recorded $530 million in cumulative sales over its first four quarters on the market
First-quarter 2024 revenues totaled $14.9 billion, a decrease of $3.6 billion, or 20%, compared to the prior-year quarter
PREVENAR offers the broadest serotype coverage of any pediatric pneumococcal conjugate vaccine to help protect infants and children from the 20 serotypes responsible for the majority of currently circulating pneumococcal disease in the EU and globally
Subject Expert Committee(SEC) of Central Drugs Standard Control Organization (CDSCO)
Pfizer plans to submit an sBLA by the end of this year, subject to discussions with U.S. FDA
Subscribe To Our Newsletter & Stay Updated
